NVO
Novo Nordisk A/S
NVO has lower modeled downside risk, despite its lower overall score.
SMTI
Sanara MedTech Inc.
SMTI has the edge over NVO overall, supported by stronger fundamentals and stronger modeled upside.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
SMTI Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Under pressure |
SMTI's cash flow is currently healthy, and its revenue and profitability are stable, but its balance sheet is under pressure.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
SMTI PE Valuation
SMTI has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
SMTI Forward outlook
There aren't enough analyst estimates for SMTI to show an outlook.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over SMTI on earnings quality, reporting a profit while its opponent remains loss making.
SMTI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.48 | +$3.74 |
| Q2 2026 | -$3.72 | -$2.56 |
| Q1 2026 | -$3.90 | -$2.56 |
| Q4 2025 | -$4.36 | -$3.22 |
| Q3 2025 | -$4.22 | -$3.23 |
| Q2 2025 | -$1.16 | -$0.38 |
| Q1 2025 | -$1.34 | -$0.75 |
| Q4 2024 | -$1.14 | -$0.62 |
SMTI lost $0.48 per share over the past year, a smaller loss than the year before.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over SMTI on profitability, with a higher operating margin.
SMTI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $28.4M | +8% |
| Q2 2026 | $28.1M | +8.9% |
| Q1 2026 | $27.8M | +19% |
| Q4 2025 | $27.5M | +4.7% |
| Q3 2025 | $26.3M | +22% |
| Q2 2025 | $25.8M | +28% |
| Q1 2025 | $23.4M | +26% |
| Q4 2024 | $26.3M | +49% |
SMTI has the edge over NVO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 2.6% | -8.6 points |
| Q2 2026 | 6.3% | +6.5 points |
| Q1 2026 | 9.5% | +18 points |
| Q4 2025 | 3.8% | +5.2 points |
| Q3 2025 | 11% | +20 points |
| Q2 2025 | -0.1% | +14 points |
| Q1 2025 | -8.9% | -0.6 points |
| Q4 2024 | -1.4% | -0.1 points |
SMTI's operating margin was 2.6% last quarter, down 8.6 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
SMTI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.9M | +250% |
| Q2 2026 | $2M | +125% |
| Q1 2026 | -$2.5M | +$1.2M |
| Q4 2025 | $3.9M | +349% |
| Q3 2025 | $1.1M | -45% |
| Q2 2025 | $902.7K | +$2.4M |
| Q1 2025 | -$3.7M | -$2.1M |
| Q4 2024 | $859.9K | +$1.8M |
SMTI has the edge over NVO on cash flow, with more consistent year-over-year improvement.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has 4.4B diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
SMTI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.4% | +120K shares |
| 1 year | -1.8% | -158K shares |
| 3 years | +5.4% | +451K shares |
| 5 years | +17% | +1.3M shares |
| Available history | +41% | +2.6M shares |
SMTI has the edge over NVO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q4 2019 | — |
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO has the edge over SMTI on leverage, with a lower net debt burden relative to earnings.
SMTI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.4x | Elevated |
| Q2 2026 | 2.9x | Moderate |
| Q1 2026 | 3.4x | Elevated |
| Q4 2025 | 5.4x | High |
| Q3 2025 | 6.1x | High |
| Q2 2025 | 50.4x | High |
SMTI's net debt is about 3.4 years of its operating earnings (EBITDA), down from 6.1 years a year ago.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
SMTI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 59.2 | Neutral |
| Stochastic | 55.3 | Neutral |
SMTI's weekly RSI is 59 (neutral) and its Stochastic is 55 (neutral).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
SMTI PE vs Healthcare Sector
SMTI has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
SMTI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $33.5 | 2.8% below |
| 20 week MA | $32.2 | 1.2% above |
| 50 week MA | $25.5 | 28% above |
| 100 week MA | $28.0 | 16% above |
| 200 week MA | $32.0 | 1.8% above |
SMTI has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
SMTI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $16.0 | $51.7 | +223% |
| 2021 | $51.7 | $25.7 | -50% |
| 2022 | $25.7 | $42.8 | +66% |
| 2023 | $42.8 | $41.1 | -4% |
| 2024 | $41.1 | $33.5 | -18% |
| 2025 | $33.5 | $24.2 | -28% |
| 2026 YTD | $24.2 | $32.5 | +34% |
SMTI has the edge over NVO on returns for 2026, with the stronger performance.